Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration (FDA) has approved TNKase ® (tenecteplase), a thrombolytic or clot-dissolving agent, for the ...
TNKase is administered as a single intravenous bolus over 5 seconds. The Food and Drug Administration (FDA) has approved TNKase ® (tenecteplase) for the treatment of acute ischemic stroke (AIS) in ...
-- Consumers Alerted to Discontinue Use of Alcohol Prep Pads Packaged with Boniva® Injection, Fuzeon®, Nutropin A.Q. Pen®, Pegasys®, TNKase® Medicines -- SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- ...
Genentech Inc. and Boehringer Ingelheim’s TNKase clot-busting drug isn’t safe for use with artery-clearing angioplasty, according to a study that was halted because of a higher death rate among those ...
Please provide your email address to receive an email when new articles are posted on . TNKase is the first stroke treatment approved by the FDA in almost 30 years, the manufacturer said. It is ...
-- Consumers Alerted to Discontinue Use of Alcohol Prep Pads Packaged with Boniva® Injection, Fuzeon®, Nutropin A.Q. Pen®, Pegasys®, TNKase® Medicines -- SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- ...
THURSDAY, March 6, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved TNKase (tenecteplase), a thrombolytic or clot-dissolving agent, for the treatment of acute ischemic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback